The most crucial measure in the directive mandates that manufacturers to test all raw materials, such as Glycerin, Propylene Glycol, and Sorbitol Solution, for DEG and EG before their use in manufacturing. The limit shall not exceed 0.10% as per the respective pharmacopoeial monographs.
In addition, all liquid oral finished products must be tested for Diethylene Glycol (DEG) and Ethylene Glycol (EG) as per the amendment to the Indian Pharmacopoeia 2022 dated 10.10.2025, without fail, with the permissible limit not exceeding 0.10%.
They are also instructed to procure pharmaceutical aids or excipients such as Glycerin, Propylene Glycol, Sorbitol Solution, etc., mandatorily directly from the manufacturers. All raw materials shall comply with pharmacopoeial standards, and only pharmacopoeial grade excipients shall be used in production.
As an abundant precaution, manufacturers shall sample and test all the individual containers or packs of Glycerin, Propylene Glycol, Sorbitol Solution, and other excipients upon receipt of raw materials.
As part of the enhanced safety protocols, manufacturers are urged to conduct in-house testing for DEG and EG by arranging Gas Chromatographs in their own Quality Control sections.
The DCA also announced that surprise inspections would be carried out at manufacturing facilities to ensure compliance with these requirements. Moreover, firms must ensure and be able to demonstrate that actual testing has been carried out and that data integrity is maintained for all test reports relating to DEG and EG content. The test reports for DEG and EG shall be periodically submitted to the Directorate of Drugs Control Administration, with a copy marked to the concerned Drugs Inspector, without fail.
The DCA has made it clear that any non-conformity or lapse in ensuring product quality leading to adverse events will attract stringent action, including the arrest and prosecution of the manufacturers and the responsible technical staff under Section 27(a) of the Drugs and Cosmetics Act, 1940, which is punishable with imprisonment for a term of not less than ten years, extendable to life imprisonment, and a fine of not less than ten lakh rupees.
Additionally, action may be initiated under Section 105 (Culpable Homicide Not Amounting to Murder) and Section 276 (Adulteration of Drugs) of the Bharatiya Nyaya Sanhita, 2023, in the event of any adverse incidents.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.